Eli Lilly to buy AtaiBeckley in $3.8 billion deal to expand mental health pipeline
Lilly will also gain VLS-01, a buccal film formulation of DMT currently in Phase 2b testing, along with AtaiBeckley's broader pipeline of next-generation neuroplastogens aimed at restoring the brain's ability to form new neural connections





















